Male study dosing
1–12 mg once weeklyRange studied in the Phase 2 trial
MGMT RESEARCHPRODUCT CONCEPT
METABOLIC RESEARCH MATERIALS
RETROD 10 mg
Retatrutide · Triple-receptor agonist
A 10 mg lyophilized research compound for investigating GLP-1, GIP, and glucagon signaling, appetite regulation, and metabolic pathways.
$100.00 CADPer vial · 10 mg option
01 / SOURCINGCanadian supplier partner
02 / QUALITYCOA pending
03 / FULFILLMENTToronto dispatch
04 / FORMATLyophilized powder
COA pending. Independent testing will be performed by SideChain Analytics in Mississauga, Ontario.
FREE BAC Water + holder with every compound vial
Every compound vial includes one free 3 mL Bacteriostatic Water and one compound / BAC pair holder. Any strength. No minimum purchase. Bundles count their included BAC Water toward this offer.
Tax-inclusive CAD pricing. E-transfer accepted · Credit cards coming soon.
Includes FREE 3 mL BAC Water + a compound / BAC pair holder with every vial.
Mix Easy · Open the calculator ↗Read RETROD | The benefits no one talks about →
Read RETROD | How long can I take it? →
Female study dosing
1–12 mg once weeklyRange studied in the Phase 2 trial
Frequency in trials
Once weeklyClinical study schedule
Route in trials
SubcutaneousInvestigational administration
Reported half-life
Approximately 6 daysHuman pharmacokinetic research
Post-cycle PCT
Not establishedNo validated PCT protocol
Phase 2 trial arms: 1, 4, 8, and 12 mg once weekly. These study doses were not separate male/female recommendations or directions for using MGMT Research vials. Published study ↗
DESCRIPTION
What is RETROD 10 mg?
RETROD is our name for Retatrutide (LY3437943), a synthetic peptide investigated for its combined activity at the GLP-1, GIP, and glucagon receptors. These pathways are involved in appetite, glucose regulation, and energy metabolism.
Your selected vial contains 10 mg of labeled lyophilized compound. This is the total vial amount, not a dose or a solution concentration. RETROD is sourced through a Canadian supplier partner and is not filled in-house by MGMT Research.
COA results are pending. Independent testing will be performed by SideChain Analytics in Mississauga, Ontario; verified purity and net-content figures will be published when available.
BENEFITS / RESEARCH INTERESTThree pathways.
Three pathways.
One research compound.
Retatrutide is studied for potential effects on body weight and metabolic health. These are research findings, not promised outcomes from this product.
- Appetite and body composition: weight-change endpoints in controlled studies.
- Glucose regulation: incretin and glucagon receptor signaling.
- Energy metabolism: investigation of multiple hormonal pathways together.
Product specifications & handling +
- Product
- RETROD · Retatrutide
- Selected quantity
- 10 mg
- Form
- Lyophilized powder
- Receptors
- GLP-1R · GIPR · GCGR
- Testing
- COA pending · SideChain Analytics
- Origin / dispatch
- Canadian supplier partner / Toronto
Follow batch-specific supplier instructions and your laboratory’s validated storage and reconstitution procedures. A prepared solution’s shelf life has not been established for this product.
Orders received before 12 PM EST ship the same business day.
COA pending. Purity and net-content results will be published when the batch-specific report is available.
MIX EASYYour mixture.
Your mixture.
Made clear.
Select your compound, vial amount, diluent volume, and sample amount. Our calculator converts your inputs into a concentration, volume, and U-100 syringe marking.
01
Set your mixture
mg
mL
Enter an example amount to calculate its volume.
02
Your measurement
RETATRUTIDE
20units
0.2 mL of solution per sample
U-100 scale1 mL = 100 units
Concentration10 mg/mL
Full samples per vial5
THE CALCULATION
2 mg ÷ 10 mg/mL = 0.2 mL
How to read this calculator +
Concentration = vial amount ÷ solution volume. Sample volume = sample amount ÷ concentration. U-100 scale units = volume in mL × 100; these are volume markings, not units of compound potency.
This example assumes the final solution volume equals the diluent volume entered, and that the compound dissolves completely. It does not establish solubility, compatibility, stability, or an administration dose.
Decimal measurements are mathematical results and may fall between markings. Full samples are rounded down; they do not account for handling losses.
The calculator checks concentration mathematics. It does not select a treatment dose or establish compatibility, sterility, or stability. SEMARO is temporarily unavailable and is omitted from this selector. BAC Water is the diluent, not a peptide.
SIDE EFFECTS & CONSIDERATIONS
What the research reports.
In the Phase 2 study, gastrointestinal adverse events were most common and increased with dose. Heart-rate increases were also observed. Longer-term safety remains under investigation.
Retatrutide remains investigational, with no regulatory approval. Research-grade MGMT Research vials are not clinical-trial medication.
Product-specific considerations
- Independent identity, purity, and content results are pending for RETROD.
- A labeled 10 mg quantity does not establish a therapeutic dose.
- Mixing calculations cannot establish sterility, stability, or suitability for administration.
DOSAGE GUIDELINES / STUDY CONTEXT
Vial amount is not a dose.
Your selected RETROD vial is labeled 10 mg. There is no approved male or female dosing regimen for this research product.
Published Phase 2 study arms
Adults were assigned 1, 4, 8, or 12 mg once weekly for 48 weeks under a controlled protocol. These are study details, not self-use instructions.
Dosing Studied in Clinical Trials
TRIUMPH-4 · 12 mg target-dose arm
Lilly reported once-weekly dosing with four-week escalation steps. Expressed as treatment weeks, the planned sequence was:
- Weeks 1–4: 2 mg once weekly
- Weeks 5–8: 4 mg once weekly
- Weeks 9–12: 6 mg once weekly
- Weeks 13–16: 9 mg once weekly
- Week 17 onward: 12 mg once weekly, the assigned target dose
The trial also included a 9 mg target-dose arm. Participants followed a controlled study protocol with clinical oversight; this is research information, not a suggested RETROD self-use or maintenance plan.
Source: Lilly’s TRIUMPH-4 study summary ↗Want the full walkthrough?
Explore the research context, vial quantities and concentration calculations in our beginner’s guide.
Read the full RETROD guide →Laboratory sample amounts and preparation procedures should come from your validated protocol. Enter those amounts into Mix Easy to check the volume calculation.
Open Mix Easy ↗Read the original trial ↗